Latest News of CYTO
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
By Yahoo! Finance |
1 month ago
A recent article highlights Cytokinetics Inc. as a promising small-cap stock for investment. It discusses the impact of interest rate cuts on small and mid-cap stocks and provides insights from expert...
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
1 month ago
Cytokinetics, Inc. shared positive results from the Phase 1 study of CK-4021586 at a medical conference. The study successfully evaluated safety, tolerability, and pharmacokinetics of CK-586, a drug b...
Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds?
By Yahoo! Finance |
1 month ago
A compilation of the 12 Best Biotech Stocks To Invest In According To Hedge Funds includes Cytokinetics, Inc. (NASDAQ:CYTK). The biotech industry is forecasted to grow significantly, with AI-driven dr...
-
Cytokinetics Shows Market Leadership With Jump To 82 RS Rating
By Investor's Business Daily | 2 months agoLearn about managing stock market exposure with incremental portfolio decisions using IBD's RS Rating. Discover how to use risk management strategies and analyze stock performance, like Cytokinetics, ...
-
Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years
By Yahoo! Finance | 3 months agoLong term investing in great businesses like Cytokinetics (NASDAQ:CYTK) can lead to significant share price growth, with a 381% gain in the last five years. Despite not being profitable, its 6.7% annu...
-
Cytokinetics Clears Technical Benchmark, Hitting 80-Plus RS Rating
By Investor's Business Daily | 3 months agoLearn how to manage your stock market exposure with incremental decisions using a unique rating system. Understand the importance of RS Rating and risk management. Discover insights on Cytokinetics an...
-
CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?
By Yahoo! Finance | 3 months agoThe article discusses the current stock market trends and focuses on CytomX Therapeutics, a biotech company listed under one-dollar stocks. Despite promising technologies, risks like financial runway ...
-
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company
By Yahoo! Finance | 3 months agoAnalyzing ownership data of a company like CytomX Therapeutics, Inc. can provide insights into future performance. Institutional investors hold a significant stake, influencing market decisions. Hedge...
-
Cytokinetics Sees IBD RS Rating Improve To 74
By Investor's Business Daily | 3 months agoIBD's RS Rating measures a stock's price performance, with high ratings indicating potential growth. Cytokinetics shows strength but is out of buy range. Look for new entry points. Check for upcoming ...
-
Cytotheryx looks to expand in Rochester and add 22 jobs
By Yahoo! Finance | 3 months agoThe Rochester City Council approved Cytotheryx's application for $870,000 state funding for a new lab building and 22 jobs. The company, co-founded by Exemplar Genetics and Mayo Clinic, plans to creat...
-
Cytora and Gamma Risk team to aid commercial property risk assessment
By Yahoo! Finance | 3 months agoCytora partners with Gamma Risk to integrate Perilfinder into its platform, enhancing insurers' risk assessment with advanced tools like address-level assessment and spatial catastrophe models. The co...
-
Nvidia, Pfizer lead $80 million funding for Israeli medical AI tech firm CytoReason
By Yahoo! Finance | 3 months agoCytoReason, an Israeli company using AI for disease models, raised $80 million in funding with investors like Nvidia and Pfizer. The company plans to expand its models, data, and open an office in Cam...
-
Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 3 months agoCytokinetics Inc is a biopharmaceutical company focused on developing therapeutics for muscle-related diseases. Insider Fady Malik sold 131,323 shares, indicating 42 sells and no buys in the past year...
-
Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 4 months agoCytokinetics Inc is a biopharmaceutical company focusing on developing muscle-modulating therapeutics. Recent insider selling trends and stock valuation indicate potential overvaluation. Investors may...
-
Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
By Yahoo! Finance | 4 months agoOn June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), sold 5,000 shares at $52.55 per share, totaling $262,750. The insider now holds 20,600 shares....